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Background/aim: Several studies demonstrated that primary hyperparathyroidism is related to increased risk for cardiovascular
diseases (CVDs), and risk is decreased by parathyroidectomy. Epicardial fat thickness (EFT) has been postulated as a new marker of
CVD risk. We evaluated the impact of parathyroidectomy on EFT in patients with primary hyperparathyroidism (PHPT).
Materials and methods: Thirty-four PHPT patients (29 female, 5 male) and 28 age- and sex-matched controls (19 female, 9 male)
were included in the study. Demographic, anthropometric, and biochemical data were recorded both before parathyroidectomy and 6
months after the procedure. Epicardial fat thickness was measured by transthoracic echocardiography.
Results: Mean age was 53.15 ± 8.44 years. Mean preoperative EFT was higher than mean EFT in the control group (0.49 ± 0.07 cm
to 0.46 ± 0.08 cm, P: 0.0005), and EFT decreased after parathyroidectomy (0.49 ± 0.07 cm to 0.44 ± 0.08 cm, P: 0.0005). Systolic
blood pressure and calcium, parathormone, and hsCRP levels decreased after parathyroidectomy (P < 0.05). Vitamin D levels increased
(P < 0.05). Diastolic blood pressure, body mass index, carotid intima-media thickness, and HOMA-IR, fasting plasma glucose, and
phosphorus levels were unchanged after parathyroidectomy (P > 0.05). Preoperatively, EFT was correlated with SBP (r: 0.360, P: 0.0285)
and age (r: 0.466, P: 0.0036). Multiple linear regression used to identify independent predictors of change in epicardial fat did not find
any predictor of change in epicardial fat (P > 0.05).
Conclusion: EFT was decreased by parathyroidectomy in patients with primary hyperparathyroidism. However, the decrease in EFT
was not correlated with any of the cardiovascular risk factors. More comprehensive studies evaluating the potential relation between
PHPT and EFT need to be conducted.
Key words: Primary hyperparathyroidism, epicardial fat thickness, cardiometabolic risk factors

1. Introduction
Primary hyperparathyroidism (PHPT) is described as
increased serum calcium and nonsuppressed parathyroid
hormone (PTH) levels [1]. The incidence of PHPT is
increasing significantly as laboratory screening tests
become more widely available [2]. Accumulating data
show that even mild PHPT leads to an elevated risk for
cardiovascular diseases (CVDs), many of which improve
after parathyroidectomy [3–7]. Epicardial fat (EF) is
present between the outer layer of the myocardium and
the inner layer of the pericardium. EF is metabolically
active and may cause inflammation and dysfunction
in the myocardium by secreting proatherogenic and
proinflammatory cytokines, as well as reactive oxygen
radicals. Increasing thickness of EF is related to higher
risk of CVD [8]. Epicardial fat thickness (EFT) can be
measured by transthoracic echocardiography [9] and is
considered a novel marker of CVD risk [10]. We evaluated

the impact of parathyroidectomy on EFT and its relation
to cardiometabolic risk factors in patients with PHPT.
2. Materials and methods
2.1. Patient selection
Thirty-four patients (29 female, 5 male) who were
diagnosed with PHPT at the Dışkapı Training and
Research Hospital between 2012 and 2016 and 28 age- and
sex-matched controls (19 female, 9 male) were enrolled in
the study. Local ethics committee approval was obtained,
and all participants provided written informed consent
before the study began. Patients with multiple endocrine
neoplasias, parathyroid cancer, thyroid cancer, or
hyperparathyroidism-jaw tumor syndrome and patients on
drugs that counteract calcium and vitamin D metabolism
were excluded from the study. A PHPT diagnosis was
made in the case of persistent hypercalcemia with normal
or nonsuppressed PTH concentrations. The decision for
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surgery was in agreement with guidelines applied at the
time of diagnosis [11].
2.2. Clinical, biochemical, and hormonal measurements
Basal demographic data, clinical features, and carotid
intima-media thickness (CIMT) measurements were
recorded for all participants. Weight, height, waist
circumference (WC), body mass index (BMI), and
systolic and diastolic blood pressure (SDP and DBP,
respectively) were measured. Fasting biochemical and
hormonal measurements were taken in the morning using
colorimetric methods, and complete blood counts were
obtained from all participants. An intact chemiluminescent
immunoassay of PTH (Immulite 2000) was used for
measuring serum PTH levels, and 25-OH vitamin D
concentrations were measured using a radioimmune assay.
EFT was calculated using a Philips IE33, a commercially
available device (Philips Electronics, USA), and was
described as the distance between the visceral and parietal
pericardium on the anterior wall of the right ventricle.
EFT was calculated vertically on the free wall of the right
ventricle in parasternal long- and short-axis views at enddiastole over 3 cardiac cycles [12]. Three measurements
were performed and the average was recorded. Highresolution B-mode ultrasound (EUB 7000 HV; Hitachi,
Japan) with a 13-MHz linear array transducer was used
to image parathyroids. CIMT was measured by B-mode
imaging high-resolution ultrasound (EUB 7000 HV;
Hitachi).
2.3. Statistical analysis
All statistical analyses were performed using JMP
13.0.1 software (SAS Institute, USA). Descriptive data
are reported as mean ± standard deviation (SD) and
percentage (%). Normality of distribution was examined
by using the Kolmogorov–Smirnov or Shapiro–Wilk W
tests. The chi-square or Fisher’s exact test was used when
variables were categorical. Student’s t-test was used for
normally distributed continuous variables, and the Mann–
Whitney U-test was used for those that did not fit a normal
distribution. Correlations were assessed using Pearson’s
and Spearman’s correlation. A multiple linear regression
model was used to identify independent predictors of
change in EF and P < 0.05 was accepted as statistical
significance.
3. Results
Thirty-four PHPT patients (29 female, 5 male) were
included in the study. Mean age was 53.15 ± 8.44 years.
The basal demographic, anthropometric, and biochemical
parameters of patients are shown in Table 1. Preoperatively,
EFT was correlated with SBP (r: 0.360, P: 0.0285) and
age (r: 0.466, P: 0.0036) (Table 2). Mean preoperative
EFT was higher than mean EFT in the control group
(0.49 ± 0.07 cm to 0.46 ± 0.08 cm, P: 0.0005). Mean EFT
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Table 1. Clinical and demographic characteristics of patients.
Mean ± SD
Age (years)

53.15 ± 8.44

BMI (kg/m )

31.66 ± 7.71

Systolic blood pressure (mmHg)

141.03 ± 19.25

Diastolic blood pressure (mmHg)

86.38 ± 8.64

Calcium (mg/dL)

11.22 ± 0.55

Phosphorous (mg/dL)

2.83 ± 1.20

Parathormone (pg/mL)

226.97 ± 253.61

Vitamin D (ng/mL)

14.27 ± 15.40

Fasting plasma glucose (mg/dL)

93.50 ± 9.44

Creatinine (mg/dL)

0.73 ± 0.20

Albumin

4.54 ± 0.32

Alkaline phosphatase

119.00 ± 42.74

LDL-cholesterol (mg/dL)

126.33 ± 30.04

Triglyceride (mg/dL)

174.82 ± 88.56

HDL-cholesterol (mg/dL)

49.27 ± 12.48

CRP (mg/L)

3.13 ± 2.6

HOMA-IR

2.64 ± 1.50

CIMT (cm)

0.67 ± 0.12

2

decreased after parathyroidectomy (0.49 ± 0.07 cm to
0.44 ± 0.07 cm, P: 0.031). Systolic blood pressure and
calcium, parathormone, and hsCRP levels decreased after
parathyroidectomy (P < 0.05). Vitamin D levels increased
(P < 0.05). Diastolic blood pressure, BMI, CIMT, and
HOMA-IR, fasting plasma glucose, and phosphorus levels
were unchanged after parathyroidectomy (P > 0.05) (Table
3). A multiple linear regression model was used to identify
independent predictors of change in EF. We did not find a
predictor of change in EF (Table 4).
4. Discussion
Our aim was to evaluate the effect of parathyroidectomy
on EFT and its relation to cardiovascular risk factors
in PHPT patients. We found that EFT decreased after
parathyroidectomy and was correlated with SBP and age.
We believe that ours is the first study to evaluate the effect
of parathyroidectomy on EFT in PHPT.
Adipose tissue is not just considered a primary site for
fat storage; it also serves as an endocrine organ by secreting
several hormones and adipokines including leptin,
adiponectin, and tumor necrosis factor-α (TNF-α), which
have proinflammatory, proatherogenic, or protective
effects and lead to negative metabolic and cardiovascular
outcomes [13,14]. Extraabdominal deposition of fat as
epicardial and intraabdominal visceral adiposity are now
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Table 2. Correlation of EFT with metabolic and biochemical
parameters.
r2

P

Systolic blood pressure (mmHg)

0.3602

0.0285

Diastolic blood pressure (mmHg)

0.152

0.369

Adenoma volume (mL)

0.1768

0.325

Age (years)

0.4662

0.0036

Calcium (mg/dL)

–0.2057

0.222

Phosphorous (mg/dL)

0.0007

0.996

Parathormone (pg/mL)

–0.0252

0.882

Vitamin D (ng/mL)

–0.2014

0.232

Fasting plasma glucose (mg/dL)

0.3228

0.058

Creatinine (mg/dL)

0.1144

0.5

LDL-cholesterol (mg/dL)

–0.2013

0.239

Triglyceride (mg/dL)

–0.013

0.94

HDL-cholesterol (mg/dL)

0.1408

0.412

Waist circumference (cm)

0.3101

0.062

CRP (mg/L)

–0.0543

0.757

HOMA-IR

–0.0276

0.881

CIMT (cm)

0.0508

0.765

BMI (kg/m2)

0.3068

0.065

suggested as markers of CVD risk [15–17]. Epicardial
fat can synthesize and release adipokines and bioactive
factors that may extend into the myocardium through
vasocrine and/or paracrine pathways. Hence, EF tissue
could be considered an endocrine organ [18]. As a result
of functional and anatomical proximity, EF has a negative
effect on coronary circulation and may lead to myocardial
dysfunction and hypertrophy, and finally to coronary
artery disease and cardiac insufficiency. EF is related to
cardiometabolic disorders such as coronary artery disease,
obesity, type 2 diabetes mellitus, and metabolic syndrome
and with CVD risk factors such as hyperlipidemia,
hypertension, obesity markers, and CIMT [8].
PTH receptors are present in cardiomyocytes,
endothelial cells, and smooth muscle cells [19], and
elevated PTH levels are related to myocardial fibrosis,
calcification, and hypertrophy [20]. Additionally, elevated
serum calcium levels are related to a higher rate of
mortality, hypertension, left ventricular hypertrophy, and
arrhythmias, as well as calcification of the myocardium,
coronary arteries, and heart valves [21]. Studies have
demonstrated that patients with PHPT had increased
cardiovascular events and mortality, and many of these
patients improved after parathyroidectomy [3–7,22].
Hypertension, hyperlipidemia, CIMT, CRP, and insulin
resistance are all well-known CVD risk factors [23,24].
Numerous cardiovascular risk factors have been shown
in patients with PHPT, including hypertension and
elevated CIMT, insulin resistance, and CRP [25–28].

Table 3. EFT and metabolic parameters before and after parathyroidectomy.
Variables

Before parathyroidectomy
(n: 33)

After parathyroidectomy
(n: 33)

Control
(n: 28)

Age (years)

53.15 ± 8.44

EFT(cm)

0.49 ± 0.07

0.44 ± 0.08

0.46 ± 0.07

0.0005

0.031

SBP (mmHg)

140.68 ± 19.25

130.99 ± 17.11

122.31 ± 10.32

0.0026

<0001

DBP (mmHg)

86.96 ± 8.64

83.96 ± 8.64

78.95 ± 5.66

0.128

<0001

BMI (kg/m2)

31.76 ± 7.71

31.09 ± 4.88

29.87 ± 3.62

0.504

0.063

Ca (mmol/L)

11.21 ± 0.55

9.55 ± 0.58

9.39 ± 0.38

<0001

<0001

P (mmol/L)

2.82 ± 1.20

3.32 ± 0.60

3.45 ± 0.51

0.050

0.0017

PTH (pg/mL)

226.96 ± 253.61

64.89 ± 33.75

61.97 ± 25.25

0.0006

<0001

25(OH)D3 (ng/mL)

14.27 ± 15.39

28.97 ± 14.87

15.64 ± 12.07

0.0007

0.767

FPG (mmol/L)

93.50 ± 9.43

94.12 ± 14.08

88.3 ± 8.31

0.733

0.0021

hsCRP (mg/L)

3.13 ± 2.6

3.82 ± 2.16

3.23 ± 2.35

0.052

0.806

CIMT (cm)

0.66 ± 0.11

0.64 ± 0.11

0.61 ± 0.12

0.388

0.049

HOMA-IR

2.63 ± 1.49

2.43 ± 1.25

2.06 ± 1.03

0.256

0.041

P*

52.57 ± 6.03

P**
0.755

*Before vs. after parathyroidectomy; data are represented as mean ± SD.
**Before parathyroidectomy vs. control.
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Table 4. Multiple linear regression model to identify independent
predictor of change in epicardial fat.
β

P

Sex

–0.152

0.489

Age

–0.296

0.180

Preoperative CRP

0.172

0.434

Adenoma size

–0.028

0.987

Preoperative PTH

–0.004

0.986

Preoperative calcium

–0.195

0.373

Preoperative BMI

0.058

0.792

Diastolic BP

–0.213

0.329

Systolic BP

–0.263

0.225

CIMT

–0.068

0.759

Asik et al. demonstrated that patients with PHPT had
increased EFT. They also found correlations between EFT
and CIMT, age, systolic blood pressure, and PTH and
serum calcium levels [29]. In light of this information,
we aimed to investigate whether EFT could be related to
cardiometabolic risk factors and whether these decreased
after parathyroidectomy in PHPT patients. In our study,

EFT was correlated with some cardiometabolic risk
factors such as SBP and age. Additionally, EFT decreased
after parathyroidectomy in these patients. However, the
decrease in EF thickness was not correlated with any of the
cardiovascular risk factors.
Our study has some limitations since it was designed as
a cross-sectional prospective study. Additionally, we had a
relatively small sample size, and the study was conducted
in a single center. We evaluated EF by 2-dimensional
echocardiography. Although echocardiography is a
relatively simple and cheap method, echocardiography
might not fully represent the amount of EF tissue due to
its 3-dimensional nature. This could be another limitation
of our study.
As a result of the anatomical and functional proximity of
EF tissue to coronary circulation, it can exert a direct effect
on CVD risk. Our study showed that parathyroidectomy
decreased the thickness of EF; however, this decrease was
not correlated with any of the cardiovascular risk factors.
More comprehensive studies evaluating the potential
relation between PHPT and EFT need to be conducted.
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